

<b>Author Year N</b>	<b>Diagnosis; Previous AD courses</b>	<b>Pharmacogenomic test platform; Data source; Timeframe</b>	<b>Patient demographics</b>	<b>Adherence</b>	<b>Cost-effectiveness</b>	<b>Harms</b>
Fagerness 2014 <sup>18</sup> 333	Any psychiatric diagnosis; NR	Genecept Assay; Claims data; 2010-2012	31.2% male 44.9 years Race NR	Guided = increase in adherence (MPR) of 6.0% (P=.00156)	Mean baseline difference in Medical cost utilization (case vs control): -\$562 (9.2%)	NR
Winner 2015 <sup>19</sup> 13,048	Any diagnosis requiring antidepressant or antipsychotic medication	GeneSight; Pharmacy benefits claims data; 2011-2013	30.76% male 51 years Race NR	Adherence = proportion of days covered Adherence improvement of 0.123 for Guided vs usual care (P<0.0001)	Guided saved \$1035.60 in total annual medication costs compared to usual care (P=0.0007)	NR

MPR=Medication Possession Ratio; NR=Not Reported